Amneal Q2 revenue beats on specialty segment growth

Amneal Pharmaceuticals

30/07/2026 11:18

Overview
US generic drugmaker's Q2 revenue rose 10% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised full-year 2026 guidance

Outlook
Amneal raises 2026 net revenue guidance to $3.10 bln-$3.20 bln from $3.05 bln-$3.15 bln
Company now sees 2026 adjusted EBITDA of $750 mln-$780 mln, up from $740 mln-$770 mln
Amneal expects 2026 adjusted diluted EPS of $0.96-$1.06, up from $0.95-$1.05

Result Drivers
SPECIALTY SEGMENT GROWTH - Specialty net revenue rose 17%, driven by branded products such as CREXONT, BREKIYA autoinjector, and UNITHROID
GENERIC AND NEW PRODUCT LAUNCHES - Affordable Medicines net revenue increased 13%, supported by strong performance in complex generics and new product launches, including women’s health products
LOWER INTEREST EXPENSE AND TAX - Higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense, boosting net income

Company press release: ID:nGNX9T40b3

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$796 mln
$768.21 mln (3 Analysts)
Q2 Adjusted EPS
Beat
$0.30
$0.22 (4 Analysts)
Q2 Net Income
 
$58 mln
 
Q2 Adjusted EBITDA
 
$206 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Amneal Pharmaceuticals Inc is $19.00, about 0.5% below its July 29 closing price of $19.10
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
July 29 - Teva Pharm profit misses estimates, seeks US tariff details
July 29 - Processa buys Vidya Therapeutics, raises $200 million for drug trials
July 28 - Incyte beats Q2 revenue estimates on strong product demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)